32 min listen
The Future of iPSCs with BlueRock Therapeutics' CEO Seth Ettenberg
The Future of iPSCs with BlueRock Therapeutics' CEO Seth Ettenberg
ratings:
Length:
29 minutes
Released:
Dec 8, 2022
Format:
Podcast episode
Description
BlueRock Therapeutics' President and CEO Seth Ettenberg, Ph.D. talks to Cell & Gene: The Podcast listeners about the company's Phase 1 Clinical Trial for Advanced Parkinson’s Disease. Ettenberg also covers the most promising therapeutic applications for iPSCs currently in development as well as the major regulatory challenges that the field faces for their clinical use. We also cover how far iPSCs have come and what future progress may entail.
Released:
Dec 8, 2022
Format:
Podcast episode
Titles in the series (76)
Therapeutic Firsts and "Eds and Meds" with Penn’s Dr. Bruce Levine by Cell & Gene: The Podcast